An open label Phase 1 safety and tolerability study of omadacycline and tigecycline in healthy adults.
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
Price : $35 *
At a glance
- Drugs Omadacycline (Primary) ; Tigecycline
- Indications Acute sinusitis; Anthrax; Community-acquired pneumonia; Nosocomial infections; Skin and soft tissue infections; Urinary tract infections
- Focus Adverse reactions
- 02 May 2017 New trial record
- 25 Apr 2017 According to a Paratek Pharmaceuticals Media Release, data was presented at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017)
- 25 Apr 2017 Results published in a Paratek Pharmaceuticals Media Release.